Home > Insider Trading > Filing (0001725160-21-000008)

Filing Details

Accession Number:: 0001725160-21-000008
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-06 20:25:41
Reporting Period:: 2021-01-04

Accepted Time:: 2021-01-06 20:25:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377952	Y Anthony Sun	C/O Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-11-22	213,600	$0.00	1,804,005	No	5	G	Direct
Common Stock	Acquisiton	2020-11-22	213,600	$0.00	213,600	No	5	G	Indirect	See Footnote
Common Stock	Disposition	2021-01-04	5,418	$50.47	1,798,587	No	4	S	Direct
Common Stock	Disposition	2021-01-04	3,951	$51.41	1,794,636	No	4	S	Direct
Common Stock	Disposition	2021-01-04	10,612	$52.47	1,784,024	No	4	S	Direct
Common Stock	Disposition	2021-01-04	6,813	$53.06	1,777,211	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	5	G	Indirect	See Footnote
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	974,302	Indirect	By Essex Group International, LLC

Footnotes

Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.805. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.83 to $51.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.84 to $52.82. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.85 to $53.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.